Cullinan Oncology, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. The filing entity was Cullinan Oncology, Inc. (the company identified in the request as Cullinan Therapeutics). Financial statements are unaudited and consolidated.
Business context
The company is a clinical-stage oncology biopharmaceutical company with no approved products and no product-sales revenue. Its lead programs included CLN-081, CLN-049 and CLN-619; it also reported earlier-stage oncology programs. CLN-081 was in a Phase 1/2a trial, while enrollment in Phase 1 trials for CLN-049 and CLN-619 began in late 2021.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| License revenue | $0 | $18.9 million |
| Research and development expense | $24.5 million | $12.4 million |
| General and administrative expense | $8.1 million | $5.2 million |
| Total operating expenses | $32.7 million | $17.6 million |
| Operating income (loss) | $(32.7) million | $1.4 million |
| Consolidated net income (loss) | $(12.9) million | $1.4 million |
| Net loss attributable to Cullinan common stockholders | $(12.1) million | $(0.1) million |
| Net loss per share, basic and diluted | $(0.27) | $(0.00) |
| Net cash used in operating activities | $(21.9) million | $(1.5) million |
Revenue in Q1 2021 was the upfront fee under the Zai Lab license agreement; no product revenue was reported. Gross margin and product margins are not meaningful because the company had no product sales. R&D expense rose 98%, mainly from higher clinical, manufacturing and chemistry, manufacturing and controls costs, early-stage research, and equity compensation. G&A expense increased 57%, primarily from equity compensation, personnel and professional services.
At March 31, 2022, cash and cash equivalents were $76.1 million, short-term investments $238.7 million, and long-term investments $94.2 million. Cash, cash equivalents and investments totaled $409.0 million; the company separately cited $314.9 million in cash, cash equivalents and short-term investments and $95.4 million in long-term investments and interest receivable. Total assets were $437.5 million, total liabilities $18.0 million and stockholders’ equity $419.5 million. The filing reports no material conventional debt; it includes a subsidiary convertible note and $1.3 million of operating lease liabilities. The $0.8 million financing proceeds from a Pearl convertible note appear in accrued liabilities with accrued interest.
Investing activities provided $34.7 million, principally reflecting maturities and sales of marketable securities exceeding purchases; this was portfolio cash management, not operating cash generation. Financing activities provided $3.5 million, including subsidiary financing and stock-option exercises. The company reported $2.3 million of unrealized investment losses in other comprehensive loss.
Material changes, outlook and risks
- The company recorded a $19.6 million income tax benefit in Q1 2022, related to expected use of current-period losses and release of valuation allowance against the expected gain from the subsequent Cullinan Pearl sale. This materially reduced reported consolidated net loss; the filing maintained a full valuation allowance on remaining net deferred tax assets.
- In May 2022, after quarter-end, the company announced an agreement for Taiho to acquire Cullinan Pearl, which holds CLN-081 rights outside Japan and Greater China. At closing, Cullinan expected $275 million upfront, subject to customary conditions, and eligibility for up to $130 million in regulatory milestones. Under a concurrent U.S. CLN-081 co-development and co-commercialization agreement, the parties would share 50% of development costs and 50% of potential U.S. pretax net profit. The transaction was pending at the filing date.
- Management expected existing cash, cash equivalents and investments to fund operations through 2024 under its current operating plan and assumptions; the sale proceeds were expected upon closing. The filing cautions that actual capital needs could arise sooner. Separately, the financial-statement liquidity note says resources were expected to cover at least the next 12 months.
- Management expects losses and R&D spending to increase as programs advance. CLN-617 and CLN-978 IND submissions were expected by the first half of 2023. No formal financial guidance beyond the stated runway and development expectations was provided.
- Management reported that CLN-081 at 100 mg twice daily had shown a 41% confirmed response rate, estimated median duration of response of 15 months and 12-month progression-free survival, with a favorable tolerability profile; these are clinical-trial results, not approval or proof of future outcomes. FDA granted CLN-081 Breakthrough Therapy Designation in January 2022.
- Key risks include clinical-trial efficacy, safety and enrollment uncertainty; reliance on third-party research and manufacturing providers; COVID-19-related enrollment, supply or operational disruption; competition, intellectual-property and regulatory risks; and the need for future financing. The company reported no material legal proceedings. Disclosure controls were judged effective at the reasonable-assurance level, with no material quarterly change in internal control over financial reporting.
Most important facts for investors to verify
- Whether and when the Taiho acquisition of Cullinan Pearl closed, the net proceeds received, and any closing adjustments or obligations.
- Whether CLN-081’s reported response, durability and safety results are confirmed in updated, adequately sized clinical data, and how the FDA’s designation affects—not guarantees—development or approval.
- Whether the projected runway through 2024 remains valid after the Pearl transaction, shared CLN-081 costs, and planned increases in development spending.
- The basis and timing of the $19.6 million tax benefit, including the expected sale gain and remaining deferred-tax valuation allowance.
- Clinical enrollment, manufacturing supply and program timelines for CLN-049, CLN-619, CLN-617 and other pipeline candidates.